For example, circulating PD-1+ early effector memory CD8+ T cells (CD28+CD27-CD45RO+) are characterized by early responses to anti-PD-1 therapy in patients with NSCLC (37). This evidence concerns the gene CD28 and non-small cell lung carcinoma.